Cytokinetics (CYTK) Set to Announce Quarterly Earnings on Wednesday

Cytokinetics (NASDAQ:CYTK) will announce its earnings results on Wednesday, February 14th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter.

Cytokinetics (NASDAQ:CYTK) opened at $8.40 on Wednesday. The company has a current ratio of 7.60, a quick ratio of 7.60 and a debt-to-equity ratio of 0.14. The stock has a market cap of $452.63, a P/E ratio of -5.06 and a beta of 1.03. Cytokinetics has a 1 year low of $7.00 and a 1 year high of $17.20.

A number of equities analysts have recently issued reports on CYTK shares. HC Wainwright restated a “buy” rating and set a $26.00 target price on shares of Cytokinetics in a research report on Friday, October 27th. Needham & Company LLC lowered shares of Cytokinetics from a “strong-buy” rating to a “buy” rating and lowered their target price for the stock from $22.00 to $12.00 in a research report on Wednesday, November 29th. Morgan Stanley restated an “overweight” rating and set a $17.00 target price (down from $25.00) on shares of Cytokinetics in a research report on Wednesday, November 22nd. ValuEngine lowered shares of Cytokinetics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 21st. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $18.00 target price on shares of Cytokinetics in a research report on Tuesday, November 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. Cytokinetics currently has a consensus rating of “Buy” and an average price target of $17.91.

ILLEGAL ACTIVITY WARNING: “Cytokinetics (CYTK) Set to Announce Quarterly Earnings on Wednesday” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2018/02/07/cytokinetics-cytk-set-to-announce-quarterly-earnings-on-wednesday.html.

Cytokinetics Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Earnings History for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply